Skip to main content

Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

Completed · Phase 3 · NCT03279081

Conditions: Crohn's Disease

At a glance

Research payments reported, 2025
$67,259
U.S. investigators named
7
Sites paid
7
Planned or actual enrollment
568

About the trial

Sponsor
Tigenix S.A.U.
Tested
Cx601 (drug), Placebo (other)
Dates
Started 2017-09-15; completion 2023-07-26
Results posted
Yes

The purpose of this study is to evaluate the combined remission of complex perianal fistulas, defined as the clinical assessment at Week 24 of closure of all treated external openings that were draining at baseline despite gentle finger compression, and absence of collections greater than (\>) 2 centimeter (cm) (in at least 2 dimensions) confirmed by blinded central magnetic resonance imaging (MRI) assessment at Week 24.

From ClinicalTrials.gov, last updated 2024-09-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $67,259 in research payments for this study in 2025 (10 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.